For de novo EBV-negative DLBCL NOS, CD30 positivity, defined by a cut-off of 20% stained lymphoma cells, ranges from 10% to 21% across different studies, with a suggested trend toward better prognosis, especially in the GCB subgroup [97,98,99,100]. The gene discussed is TNFRSF8; the disease is lymphoma.